Estrogen or raloxifene during postmenopausal weight loss: adiposity and cardiometabolic outcomes
RE Van Pelt, WS Gozansky, P Wolfe, JM Kittelson… - …, 2014 - Wiley Online Library
Obesity, 2014•Wiley Online Library
Objective Estrogen‐based hormone therapy (HT) attenuates abdominal fat gain after
menopause, but whether HT improves abdominal fat loss during weight loss is unknown. It
was hypothesized that HT or a selective estrogen receptor modulator (raloxifene) would
augment reductions in abdominal visceral fat during weight loss when compared to placebo,
potentially increasing improvements in glucose tolerance and lipid profile. Methods Healthy
postmenopausal women (n= 119; age 50‐70 yr) underwent a 6‐month weight‐loss …
menopause, but whether HT improves abdominal fat loss during weight loss is unknown. It
was hypothesized that HT or a selective estrogen receptor modulator (raloxifene) would
augment reductions in abdominal visceral fat during weight loss when compared to placebo,
potentially increasing improvements in glucose tolerance and lipid profile. Methods Healthy
postmenopausal women (n= 119; age 50‐70 yr) underwent a 6‐month weight‐loss …
Objective
Estrogen‐based hormone therapy (HT) attenuates abdominal fat gain after menopause, but whether HT improves abdominal fat loss during weight loss is unknown. It was hypothesized that HT or a selective estrogen receptor modulator (raloxifene) would augment reductions in abdominal visceral fat during weight loss when compared to placebo, potentially increasing improvements in glucose tolerance and lipid profile.
Methods
Healthy postmenopausal women (n = 119; age 50‐70 yr) underwent a 6‐month weight‐loss (primarily exercise) intervention with randomization to raloxifene (60 mg/d), HT (conjugated estrogens, 0.625 mg/d), or placebo. Outcomes were change in total and abdominal (visceral and subcutaneous) fat mass, lipid profile, and fasting and post‐challenge glucose and insulin.
Results
Neither HT nor raloxifene augmented loss of total or abdominal fat mass during exercise‐induced weight loss when compared with placebo. Weight loss‐induced improvements in risk factors were similar among the three groups, except for a greater reduction in fasted glucose in the HT group (difference in change [95%CI] from placebo; −0.40 [−0.76, −0.05]) and greater reductions in LDL (−0.36 [−0.63, −0.09]) and increases in HDL (0.15 [0.07, 0.24]) in both treatment groups.
Conclusions
Postmenopausal HT and raloxifene did not increase abdominal fat loss during weight loss, but did improve some cardiometabolic outcomes.
Wiley Online Library